Review
doi: 10.1098/rstb.2005.1702.
CAMPATH: from concept to clinic
Affiliations
- PMID: 16147535
- PMCID: PMC1569536
- DOI: 10.1098/rstb.2005.1702
Item in Clipboard
Review
CAMPATH: from concept to clinic
Philos Trans R Soc Lond B Biol Sci.
.
Abstract
Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity diseases.
Similar articles
-
CAMPATH-1 antibodies in stem-cell transplantation.Cytotherapy. 2001;3(3):145-64. doi: 10.1080/146532401753173981. Cytotherapy. 2001. PMID: 12171722
-
Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?Transplant Proc. 2004 Jun;36(5):1225-7. doi: 10.1016/j.transproceed.2004.05.067. Transplant Proc. 2004. PMID: 15251298
-
T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?BioDrugs. 2003;17(3):147-54. doi: 10.2165/00063030-200317030-00001. BioDrugs. 2003. PMID: 12749751 Review.
-
Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.Cytotherapy. 2008;10(1):45-53. doi: 10.1080/14653240701732771. Cytotherapy. 2008. PMID: 18202974
-
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?Bone Marrow Transplant. 2002 Dec;30(12):797-804. doi: 10.1038/sj.bmt.1703733. Bone Marrow Transplant. 2002. PMID: 12476271 Review.
Cited by
-
In search of magic bullets: the golden age of immunotherapeutics.Cell. 2014 Mar 27;157(1):227-40. doi: 10.1016/j.cell.2014.03.010. Cell. 2014. PMID: 24679538 Free PMC article. Review.
-
Alemtuzumab as Treatment for Multiple Sclerosis.Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a032029. doi: 10.1101/cshperspect.a032029. Cold Spring Harb Perspect Med. 2018. PMID: 29500306 Free PMC article. Review.
-
Prediction and analysis of antibody amyloidogenesis from sequences.PLoS One. 2013;8(1):e53235. doi: 10.1371/journal.pone.0053235. Epub 2013 Jan 7. PLoS One. 2013. PMID: 23308169 Free PMC article.
-
Alemtuzumab therapy for multiple sclerosis.Neurotherapeutics. 2013 Jan;10(1):29-33. doi: 10.1007/s13311-012-0159-0. Neurotherapeutics. 2013. PMID: 23184314 Free PMC article. Review.
-
Alemtuzumab in allogeneic hematopoetic stem cell transplantation.Expert Opin Biol Ther. 2011 Aug;11(8):1099-111. doi: 10.1517/14712598.2011.592824. Epub 2011 Jun 27. Expert Opin Biol Ther. 2011. PMID: 21702703 Free PMC article.
References
-
- Axelrod D, Leventhal J.R, Gallon L.G, Parker M.A, Kaufman D.B. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. Am. J. Transplant. 2005;5:1423–1429. - PubMed
-
- Calne R, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999;68:1613–1616. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
